Abstract
We have detected somatostatin receptors (SSR) by autoradiography in 3/4 established small cell lung cancer (SCLC) cell lines but not in two non-SCLC cell lines. The growth of 1/3 SSR positive SCLC cell lines was significantly inhibited by the long-acting somatostatin analogue octreotide (SMS 201-995, Sandostatin) 10(-9) M. We treated 20 SCLC patients with octreotide 250 micrograms three times daily for 1 week prechemotherapy (six patients) or at relapse after chemotherapy (14). Octreotide was well tolerated, and serum insulin-like growth factor-I levels were suppressed to 62 +/- 7% of pre-treatment levels. However there was no evidence of anti-tumour activity measured by tumour bulk or serum levels of neuron-specific enolase. In one patient metastatic skin nodules were shown to be SSR positive before and at the end of 2 weeks octreotide. Despite this the patient had progressive disease, and tumour cells obtained by fine needle aspirate before and after treatment showed no growth inhibition when cultured with octreotide immediately or following establishment as a cell line. In summary we saw little correlation between SSR expression and growth inhibition by octreotide, either in vitro or clinically.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Macaulay, V., Smith, I., Everard, M. et al. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer 64, 451–456 (1991). https://doi.org/10.1038/bjc.1991.330
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.330
This article is cited by
-
Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer
Journal of Cancer Research and Clinical Oncology (2018)
-
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside
European Journal of Nuclear Medicine and Molecular Imaging (2015)
-
Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors
Journal of Endocrinological Investigation (2007)
-
Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities
European Journal of Nuclear Medicine (1996)
-
The diagnostic utility of somatostatin receptor scintigraphy in oncology
Journal of Cancer Research and Clinical Oncology (1996)